Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
单位：[1]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany[2]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America[3]Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, United States of America[4]National Clinical Research Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China[5]Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, United Kingdom[6]National Heart and Lung Institute, Imperial College London, London, United Kingdom[7]AstraZeneca, Durham, NC, United States of America[8]AstraZeneca, Morristown, NJ, United States of America[9]AstraZeneca, Gaithersburg, MD, United States of America[10]AstraZeneca, Gothenburg, Sweden
第一作者单位：[1]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany[*1]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany
通讯作者：
通讯机构：[1]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany[*1]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany
推荐引用方式(GB/T 7714)：
Rabe Klaus F.,Martinez Fernando J.,Ferguson Gary T.,et al.Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis[J].EUROPEAN RESPIRATORY JOURNAL.2020,56:doi:10.1183/13993003.congress-2020.984.
APA：
Rabe, Klaus F.,Martinez, Fernando J.,Ferguson, Gary T.,Wang, Chen,Singh, Dave...&Dorinsky, Paul.(2020).Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis.EUROPEAN RESPIRATORY JOURNAL,56,
MLA：
Rabe, Klaus F.,et al."Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis".EUROPEAN RESPIRATORY JOURNAL 56.(2020)
医学